GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Future 3-5Y EPS without NRI Growth Rate

DHR (Danaher) Future 3-5Y EPS without NRI Growth Rate : 8.93 (As of Mar. 24, 2025)


View and export this data going back to 1986. Start your Free Trial

What is Danaher Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Danaher's Future 3-5Y EPS without NRI Growth Rate is 8.93.


Competitive Comparison of Danaher's Future 3-5Y EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Danaher's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Danaher's Future 3-5Y EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Danaher's Future 3-5Y EPS without NRI Growth Rate falls into.



Danaher  (NYSE:DHR) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Danaher Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Danaher's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Danaher Business Description

Industry
Address
2200 Pennsylvania Avenue, North West, Suite 800W, Washington, DC, USA, 20037-1701
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Executives
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854